Novo Nordisk (NVO) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanding the use of Alhemo to more haemophilia patients.
The update would allow Alhemo to treat adults and children aged 12 and up with severe haemophilia A or moderate to severe haemophilia B without inhibitors.
The recommendation is based on a phase 3 trial that showed Alhemo significantly reduced spontaneous and traumatic bleeding compared with no prophylaxis.
The treatment also showed a favorable safety profile when delivered via a pen-injector device.
Novo Nordisk said it expects the European Commission to approve the label update within about two months.
The company's shares were up 1% in recent trading.
Price: 71.44, Change: +0.71, Percent Change: +1.00
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。